Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 19, 2019updated 20 Mar 2019 11:15am

Novo Nordisk settles Victoza patent dispute with Teva in US

Danish pharmaceutical company Novo Nordisk has reached an agreement with Teva Pharmaceuticals USA to settle the patent dispute in the US over its type 2 diabetes drug Victoza.

Danish pharmaceutical company Novo Nordisk has reached an agreement with Teva Pharmaceuticals USA to settle the patent dispute in the US over its type 2 diabetes drug Victoza (liraglutide).

As part of the settlement, Teva can introduce a generic version of Victoza from 22 December 2023.

The company would only be able to launch its own Victoza generic before this date if Novo Nordisk’s patent were lifted or another company started to market a Victoza generic.

If Novo Nordisk secures six months paediatric extension for the drug, all these timeframes will be extended by six months.

The settlement agreement is subject to review by the US Federal Trade Commission and the US Department of Justice.

Novo Nordisk Biopharm and Legal Affairs executive vice-president and head Jesper Brandgaard said: “This settlement reflects the comprehensive US patent portfolio for liraglutide. Novo Nordisk will continue to defend our broad intellectual property portfolio for innovative drugs against challenges.”

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This settlement reflects the comprehensive US patent portfolio for liraglutide.”

Available in pre‑filled pens, Victoza is indicated for once-daily use in conjunction with diet and exercise to improve glycaemic control in adults suffering from type 2 diabetes.

The medicine is an ‘incretin mimetic’ and belongs to a class of glucagon-like peptide-1 (GLP-1) receptor agonists. It works by increasing the amount of insulin generated by the pancreas in response to food. This mechanism is intended to help control blood glucose levels.

IMS Health statistics reveal that the drug recorded approximately $3.2bn in total US sales for the 12 months ending 31 December 2016.

According to data from six main clinical studies conducted in a total of 4,155 patients, Victoza demonstrated effectiveness in controlling the blood glucose.

The drug secured European Commission (EC) marketing authorisation in 2009, followed by the US Food and Drug Administration (FDA) approval in 2010. Teva Pharmaceutical Industries submitted an abbreviated new drug application (ANDA) to the FDA for approval of a generic version of Victoza in 2017.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU